Wall Street analysts expect Gilead Sciences (GILD) to post quarterly earnings of $1.73 per share in its upcoming report, which indicates a year-over-year increase of 231.1%. Revenues are expected to ...

Gilead Sciences' leading HIV business might face a slowdown in 2025, even though a potential approval of lenacapavir would be ...

The Trump administration's cuts to HIV prevention will lead to new infections, medical costs and death, experts warn.

Focused on elevating Abu Dhabi as a hub for groundbreaking medical research, the partnership aims to enhance treatment ...

At current levels, we believe GILD scores above BMY, buoyed by solid fundamentals, potential approval of lenacapavir for HIV ...

We recently published a list of the 11 Most Undervalued Quality Stocks to Buy Now. In this article, we are going to take a ...

Research in the Sundquist lab laid the foundations for the development of lenacapavir, a drug that prevents HIV infection ...

Delve into the landscape of biotech companies developing treatments for HIV and find out if we are getting closer to a cure.

Wesley Sundquist, a biochemist at University of Utah, and Tomas Cihlar, a virologist at Gilead, a biopharmaceutical company, ...

Wesley Sundquist, a biochemist at University of Utah, and Tomas Cihlar, a virologist at Gilead, a biopharmaceutical company, ...

Johnson & Johnson’s Joaquin Duato is no longer the highest paid CEO in pharma. Meanwhile, just two women make the top 10.

In a sliding market, Gilead Sciences has defied the odds, trading up to $106.42 per share. Its 24% gain since October 2024 ...